Corcept Therapeutics (CORT) Non Operating Interest Expenses (2011 - 2012)
Corcept Therapeutics (CORT) reported Non Operating Interest Expenses of $1.1 million for Q4 2012, up 14200.0% on a YoY basis from N/an in Q1 2012, and up 83.92% sequentially from $622000.0 in Q3 2012.
Corcept Therapeutics (CORT) Non Operating Interest Expenses (2011 - 2012) Analysis & Trends
Corcept Therapeutics (CORT) has 2 years of Non Operating Interest Expenses data on file, last reported at $1.1 million in Q4 2012.
- For the quarter ending Q4 2012, Non Operating Interest Expenses rose 14200.0% year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2012 stood at $1.8 million (changed N/A YoY), and the FY2012 full-year result was $1.8 million, up 7004.0% from the prior year.
- Non Operating Interest Expenses improved to $1.1 million in Q4 2012, from $622000.0 in the prior quarter.
- In the past five years, Non Operating Interest Expenses ranged from a high of $1.1 million in Q4 2012 to a low of $1000.0 in Q3 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -220,921.81 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Corcept Therapeutics | 9.99 Bn | 9.65 Bn | 162.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 1.14 Mn |
| Sep 30, 2012 | 622,000.00 |
| Dec 31, 2011 | 8,000.00 |
| Sep 30, 2011 | 1,000.00 |